Showing results (1001-1010 of 1,095) with videos related to
Sort By:
Pageof 110
Plos One|November 14, 2019
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approachAlessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLCPasi A Jänne, Yasushi Goto, Toshio Kubo, et al.Cell|October 9, 2020
Lactate Elicits ER-Mitochondrial Mg<sup>2+</sup> Dynamics to Integrate Cellular MetabolismCassidy C Daw, Karthik Ramachandran, Benjamin T Enslow, et al.Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Timing and structure of the Younger Dryas event and its underlying climate dynamicsHai Cheng, Haiwei Zhang, Christoph Spötl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.Journal of Experimental & Clinical Cancer Research : CR|May 11, 2023
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activityFrancesca Bersani, Francesca Picca, Deborah Morena, et al.JCO Precision Oncology|September 10, 2025
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?Riziero Esposito Abate, Alessandro Morabito, Michele Milella, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2022
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, et al.Journal of Experimental & Clinical Cancer Research : CR|August 6, 2024
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancerMuhlis Akman, Ciro Monteleone, Gabriella Doronzo, et al.Pageof 110